This bindingprocess stimulates production of a protein called interleukin-10 (IL-10) that acts as an anti-inflammatory compound and which helps keep the immune system's response to the infection in check.
An antisense drug, designed to look like the original DNA, could interrupt that process by binding to a complementary stretch of RNA and destroying it.
Such therapy includes strengthening the remaining limb and a process called "limb shaping, " in which binding materials are used to create more cylindrical stumps that fit into prosthetics.